CA
NZ
UK
AU
IND
US
If you're watching Zoetis (NYSE:ZTS), the stock is essentially holding steady in pre-market trading as the market weighs a new positive regulatory catalyst against broader concerns about softening U.S. companion-animal demand. The FDA has authorized Simparica Trio, already the first product approved to provide …
Eton Pharmaceuticals (NASDAQ:ETON) shares are surging in pre-market trading, up roughly 23% to around $50, after the company reportedBlowoutsecond-quarter 2026 results driven by the HEMANGEOL relaunch and broad rare-disease portfolio growth. Revenue nearly doubled year-over-year to $37.6 million, topping the $27.1 million consensus, while …
Boston Scientific (NYSE:BSX) shares are climbing in pre-market trading, building on a recovery that began after a sharp selloff earlier this year triggered by a cut to full-year 2026 organic growth guidance. The rally is being reinforced by notable insider buying: CEO Michael F. …
● Tenon Medical posted record second-quarter revenue, its strongest quarterly sales performance to date.
● Curis priced a $5.6 million raise carrying an explicit going-concern warning, underscoring the company's thin financial cushion.
● Eloxx Pharmaceuticals returned to trading on the Nasdaq Capital Market, less than three years after being removed from the exchange.
● Ernexa Therapeutics is lining up a third-quarter IND filing for lead candidate ERNA-101, its first application to test the drug in humans.
● GRI Bio won FDAOrphan DrugDesignation for lung-fibrosis candidate GRI-0621, a meaningful regulatory milestone.
● The company simultaneously advanced an FDA meeting request tied to its solid-tumor T-cell engager program.
● Moleculin Biotech reported a 37% blinded remission rate in venetoclax-failed AML patients, a fresh interim look at its most important ongoing trial.
Please wait processing your request...